Chloé E. Atreya

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le, Tae Won Kim, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer

Ryan B. Corcoran, Thierry André, Chloé E. Atreya et al. · Cancer Discovery · 2018 · 583 citations · Full text

Medicine, Oncology, Pharmacology +17

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 512 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz, Katherine A. Guthrie, Van K. Morris et al. · Journal of Clinical Oncology · 2020 · 391 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer

John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian et al. · Cancer Discovery · 2017 · 308 citations

Medicine, Molecular Biology, Oncology +17